ICMJE DISCLOSURE FORM

10/12/2023

Date:

| Your Name: | | | W. Taal | | | |
|--|---|--------|--|---|--|--|
| Manuscript Title: | | | Symptomatische tumoren bij volwassenen met Neurofibromatose type 1: een diagnostische uitdaging. | | | |
| Manuscript Number (if known): | | nown): | D7864 | | | |
| In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so. The author's relationships/activities/interests should be defined broadly. For example, if your manuscript pertains to the | | | | | | |
| epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript. | | | | | | |
| In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months. | | | | | | |
| | | | l entities with whom you have this ship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | |
| | | | Time frame: Since the initial planning | of the work | | |
| 1 | All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. | | one | (lick the tankes to ado additional rows, | | |
| | , | | Time frame: past 36 month | S | | |
| 2 | Grants or contracts from any entity (if not indicated in item #1 above). | Novart | one is grant (150k) for study with Trametinib in RAIN study). Not related to this manustript | Payment to the institution (Erasmus MC) | | |
| 3 | Royalties or licenses | N N | one | | | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) |
|----|--|--|---|
| 4 | Consulting fees | None | |
| 5 | Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events | None | |
| 6 | Payment for expert testimony | None | |
| 7 | Support for attending meetings and/or travel | None | |
| 8 | Patents planned, issued or pending | None | |
| 9 | Participation on a Data Safety Monitoring Board or Advisory Board | ■ None | |
| 10 | Leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid | None | |

| | | Name all entities with whom you have this relationship or indicate none (add rows as needed) | Specifications/Comments (e.g., if payments were made to you or to your institution) | | | |
|---|--|--|---|--|--|--|
| 11 | Stock or stock options | ⊠ None | | | | |
| 12 | Receipt of equipment, materials, drugs, medical writing, gifts or other services | Novartis provides medication (trametinib) for TRAIN study (not related to this manuscript) | | | | |
| 13 | Other financial or non-financial interests | None | | | | |
| Please place an "X" next to the following statement to indicate your agreement: | | | | | | |
| | I certify that I have answered every question and have not altered the wording of any of the questions on this form. | | | | | |